Loading…
Develops and sells non-surgical treatments for urothelial (bladder) cancers using a proprietary reverse-thermal gel.
Develops and sells non-surgical treatments for urothelial (bladder) cancers using a proprietary reverse-thermal gel.
Sells through specialty distributors to urology practices and hospitals, which are reimbursed by Medicare and insurers, so reimbursement coding matters. Jelmyto, approved in 2020, carries sales; Zusduri, aimed at a larger group of bladder-cancer patients, is the second product.
Moat: narrow (IP / patents, regulatory licence). Proprietary sustained-release gel formulation applied to an underserved non-surgical bladder cancer niche.
Headquarters: Princeton, New Jersey, US · Founded: 2004 · Employees: 291
Size UroGen Pharma (URGN) is a United States Health Care company (Biotechnology) with a market value of $1.21B, the 2135th largest of 3,117 United States companies the cockpit tracks. Shares closed at $24.75 on 6 Nov 2026.
Performance Over six months the shares fell 15.8%, against -10.0% for the median peer and -1.1% for the United States market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 159.3% over the last twelve months (peer median -4.6%); the operating margin is -12.4% (peer median -81.3%).
Valuation It trades at 13.9× forward earnings against a peer median of 31.0× (2nd cheapest of 8).
Short interest Short interest is 11.5% of the free float (15 Oct 2026).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $250M | $110M | $90.4M | $82.7M | $64.4M |
| Revenue growth | — | +21% | +9% | +29% | — |
| Gross profit | $229M | $97.3M | $81.5M | $73.4M | $56.7M |
| EBITDA | -$28.2M | -$122M | -$95.6M | -$63.8M | -$77.2M |
| Net income | -$65.8M | -$153M | -$127M | -$102M | -$110M |
| Free cash flow | -$137M | -$163M | -$97.1M | -$76.6M | -$87.8M |
| Capital expenditure | $208,776 | $289,000 | $295,000 | $194,000 | $254,000 |
| Total debt | $196M | $130M | $125M | $100M | $100M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| UroGen Pharma URGN | $1.21B | -16% | +159% | -12% | 13.9× | n/a |
| Merck & MRK | $362B | +33% | +5% | 18% | 17.4× | 4.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | URGN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -33.1% | -4.6% | 2nd lowest of 21 |
| 6-month return | -15.8% | -10.0% | 9th lowest of 21 |
| Distance from 52-week high | -51.3% | -39.1% | 4th lowest of 21 |
| Revenue growth (TTM) | +159.3% | -4.6% | 4th highest of 16 |
| Operating margin | -12.4% | -81.3% | 8th highest of 16 |
| Forward P/E | 13.9× | 31.0× | 2nd cheapest of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| UroGen Pharma URGN | United States | $1.21B | -16% | +159% | -12% | 13.9× | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.22B | -13% | n/a | n/a | n/a | n/a | n/a |
| Vor Biopharma VOR | United States | $1.22B | +17% | n/a | n/a | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 27.0× | 15.8% | +9.9% |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.17B | -36% | n/a | -838% | n/a | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 31.0× | 16.4% | -5.8% |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 46.2× | 8.8% | -7.0% |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | n/a | 5.7% | -32.3% |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 29.4× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | n/a | n/a | n/a |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 8.6× | -1.2% | +25.6% |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 42.8× | 36.5% | -13.1% |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | n/a | n/a | n/a |
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | n/a | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $1.02B | -4% | -28% | 11% | 103.0× | 42.9% | -16.6% |